[Heart and blood: clonal hematopoiesis]

Area of Science:

• Hematology
• Cardiology
• Genetics

Context:

• Cardiovascular diseases (CVDs) are a leading global cause of mortality.
• Traditional risk factors include smoking, obesity, and hypertension.
• Clonal hematopoiesis, originating from stem cell mutations, is an emerging risk factor.

Purpose:

• To highlight clonal hematopoiesis of indeterminate potential (CHIP) as a novel cardiovascular risk factor.
• To explore the association between CHIP mutations and cardiovascular diseases.
• To discuss the prognostic implications of CHIP in cardiovascular patients.

Summary:

• Clonal hematopoiesis arises from mutations in hematopoietic stem cells, leading to expanded mutated cell clones.
• CHIP, while minimally increasing leukemia risk, significantly elevates the risk of atherosclerotic vascular diseases, stroke, and thrombosis.
• Patients with heart failure (HFrEF and HFpEF) show increased mutated cell counts, and CHIP presence correlates with worse outcomes.

Impact:

• Identifies CHIP as a significant, blood-based risk factor for cardiovascular diseases.
• Suggests CHIP mutations may influence disease progression and prognosis in cardiovascular patients.
• Underscores the need for further research into CHIP's specific mechanisms and potential therapeutic interventions, including anti-inflammatory drugs.